Literature DB >> 2113075

A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals.

P Nishanian1, K R Huskins, S Stehn, R Detels, J L Fahey.   

Abstract

Improved detection and quantitation of p24 antigen of the human immunodeficiency virus (HIV) in sera was obtained by pH 2.5-3.0 pretreatment of samples before using a standard HIV p24 antigen ELISA. Pretreatment dissociated immune complexes and denatured antibodies with little or no compromise of p24 antigen immunoreactivity. For 652 HIV antibody-positive sera, direct comparison of the pretreatment with the conventional assay demonstrated substantial increase in both antigen positivity (50.6% vs. 12.4%) and in the level of p24 antigen in sera. Serum HIV antigen is mainly in the form of immune complexes in most individuals at all stages of HIV infection. Longitudinal study of 1 year (three measurements) on 29 seroconverters demonstrated two main patterns of p24 antigen expression in sera: 34.5% of infected individuals never express any form of detectable HIV antigen and 58.6% persistently demonstrate serum p24 antigen, usually in complex with antibody. Only 6.9% show episodic p24 antigen positivity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2113075     DOI: 10.1093/infdis/162.1.21

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Characterization of immune responses to capsid protein p24 of human immunodeficiency virus type 1 and implications for detection.

Authors:  Shixing Tang; Jiangqin Zhao; Aifeng Wang; Ragupathy Viswanath; Harri Harma; Richard F Little; Robert Yarchoan; Susan L Stramer; Phillipe N Nyambi; Sherwin Lee; Owen Wood; Eric Y Wong; Xue Wang; Indira K Hewlett
Journal:  Clin Vaccine Immunol       Date:  2010-06-09

2.  Improved detection of HIV p24 antigen in serum after acid pretreatment.

Authors:  M A Rodríguez-Iglesias; J R Alvarez; A Vergara; M S Garcia-Valdivia; I Jesús; J Mira
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

3.  Not your Typical Rash: A Case of IgA Nephropathy in the Setting of HIV.

Authors:  Pamela Contreras-Chavez; Andrea Anampa-Guzmán; Jose Henao; Raynieri Fernandez; Peguy Saad
Journal:  Cureus       Date:  2019-08-12

Review 4.  Cytokines, plasma immune activation markers, and clinically relevant surrogate markers in human immunodeficiency virus infection.

Authors:  J L Fahey
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

Review 5.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

6.  Stabilities of free and complexed human immunodeficiency virus p24 antigens during short- and long-term storage.

Authors:  M Arens; W Meyer; D Brambilla; J Bremer; S Fiscus; B Griffith; S Hammer; R Hodinka; W Kabat; B Yen-Lieberman; L Myers; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

7.  Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  H Revets; D Marissens; S de Wit; P Lacor; N Clumeck; S Lauwers; G Zissis
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

8.  Mycobacterium avium infection in HIV-1-infected subjects increases monokine secretion and is associated with enhanced viral load and diminished immune response to viral antigens.

Authors:  M Denis; E Ghadirian
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

9.  Clinical utility of an enhanced human immunodeficiency virus type 1 p24 antigen capture assay.

Authors:  M B Vasudevachari; N P Salzman; D R Woll; C Mast; K W Uffelman; G Toedter; D Hoefheinz; J A Metcalf; H C Lane
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

10.  In vitro anti-HIV-1 antibody production in subjects in different stages of HIV-1 infection.

Authors:  S Rusconi; A Riva; L Meroni; G Zehender; F Cocchi; L Scapellato; M Galli
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.